| Synonym |
| Thai / English name |
Part Used : รากActivity : DRUG INTERACTIONSolvent/Active Compound : ginsenoside Rg3Type of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : CT-26 cell-inoculated group treated with 5 mg/kg Rg3 plus 5 mg/kg cisplatin, once daily.Duration : 15 daysType of interaction : PharmacodynamicsInteraction with drug : Cisplatin*/CDDPDose/Conc.(drug) : -Result : PositiveRemark : To assess the effect of Rg3 on tumor growth and cisplatin toxicity. Result: Mice that received a combination of 5 mg/kg Rg3 and 5 mg/kg cisplatin showed reductions in tumor growth of 87% (84% for mice treated with cisplatin alone).Note : CT-26 mouse colon cancer cells (2x10^6 cells) suspended in 0.1 ml phosphate buffered saline (PBS) were subcutaneously injected into the right flanks of the mice. Twenty-four hours later, the mice were given Rg3 (5 or 10 mg/kg body weight (BW)) in PBS via oral gavage. Two hours later, cisplatin (2 or 5 mg/kg BW) dissolved in PBS was intraperitoneally injected. Rg3 and/or cisplatin were administered once per day for 15 days.
Part Used : รากActivity : DRUG INTERACTIONSolvent/Active Compound : ginsenoside Rg3Type of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : CT-26 cell-inoculated group treated with 10 mg/kg Rg3 plus 5 mg/kg cisplatin, once daily.Duration : 15 daysType of interaction : PharmacodynamicsInteraction with drug : Cisplatin*/CDDPDose/Conc.(drug) : -Result : PositiveRemark : To assess the effect of Rg3 on tumor growth and cisplatin toxicity. Result: Mice that received a combination of 10 mg/kg Rg3 and 5 mg/kg cisplatin showed reductions in tumor growth of 93% (84% for mice treated with cisplatin alone).Note : CT-26 mouse colon cancer cells (2x10^6 cells) suspended in 0.1 ml phosphate buffered saline (PBS) were subcutaneously injected into the right flanks of the mice. Twenty-four hours later, the mice were given Rg3 (5 or 10 mg/kg body weight (BW)) in PBS via oral gavage. Two hours later, cisplatin (2 or 5 mg/kg BW) dissolved in PBS was intraperitoneally injected. Rg3 and/or cisplatin were administered once per day for 15 days.
Part Used : รากActivity : DRUG INTERACTIONSolvent/Active Compound : ginsenoside Rg3Type of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : CT-26 cell-inoculated group treated with 5 mg/kg Rg3 plus 2 mg/kg cisplatin, once daily.Duration : 15 daysType of interaction : PharmacodynamicsInteraction with drug : Cisplatin*/CDDPDose/Conc.(drug) : -Result : PositiveRemark : To determine whether Rg3 could improve the anticancer effect of cisplatin. Result: Co-administration of Rg3 and cisplatin resulted in a more significant inhibition of tumor growth compared with mice treated with cisplatin alone.Note : CT-26 mouse colon cancer cells (2x10^6 cells) suspended in 0.1 ml phosphate buffered saline (PBS) were subcutaneously injected into the right flanks of the mice. Twenty-four hours later, the mice were given Rg3 (5 or 10 mg/kg body weight (BW)) in PBS via oral gavage. Two hours later, cisplatin (2 or 5 mg/kg BW) dissolved in PBS was intraperitoneally injected. Rg3 and/or cisplatin were administered once per day for 15 days.
Part Used : รากActivity : DRUG INTERACTIONSolvent/Active Compound : ginsenoside Rg3Type of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : CT-26 cell-inoculated group treated with 10 mg/kg Rg3 plus 2 mg/kg cisplatin, once daily.Duration : 15 daysType of interaction : PharmacodynamicsInteraction with drug : Cisplatin*/CDDPDose/Conc.(drug) : -Result : PositiveRemark : To determine whether Rg3 could improve the anticancer effect of cisplatin. Result: Co-administration of Rg3 and cisplatin resulted in a more significant inhibition of tumor growth compared with mice treated with cisplatin alone.Note : CT-26 mouse colon cancer cells (2x10^6 cells) suspended in 0.1 ml phosphate buffered saline (PBS) were subcutaneously injected into the right flanks of the mice. Twenty-four hours later, the mice were given Rg3 (5 or 10 mg/kg body weight (BW)) in PBS via oral gavage. Two hours later, cisplatin (2 or 5 mg/kg BW) dissolved in PBS was intraperitoneally injected. Rg3 and/or cisplatin were administered once per day for 15 days.
Part Used : รากActivity : DRUG INTERACTIONSolvent/Active Compound : ginsenoside Rg3Type of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : CT-26 cell-inoculated group treated with 5 mg/kg Rg3 plus 5 mg/kg cisplatin, once daily.Duration : 15 daysType of interaction : PharmacodynamicsInteraction with drug : Cisplatin*/CDDPDose/Conc.(drug) : -Result : PositiveRemark : Result: Co-administration of Rg3 and cisplatin more substantially inhibited the expression of Ki-67, VEGF and CD34 and enhanced apoptosis compared with mice treated with Rg3 or cisplatin alone.Note : CT-26 mouse colon cancer cells (2x10^6 cells) suspended in 0.1 ml phosphate buffered saline (PBS) were subcutaneously injected into the right flanks of the mice. Twenty-four hours later, the mice were given Rg3 (5 or 10 mg/kg body weight (BW)) in PBS via oral gavage. Two hours later, cisplatin (2 or 5 mg/kg BW) dissolved in PBS was intraperitoneally injected. Rg3 and/or cisplatin were administered once per day for 15 days.
Part Used : รากActivity : DRUG INTERACTIONSolvent/Active Compound : ginsenoside Rg3Type of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : CT-26 cell-inoculated group treated with 10 mg/kg Rg3 plus 5 mg/kg cisplatin, once daily.Duration : 15 daysType of interaction : PharmacodynamicsInteraction with drug : Cisplatin*/CDDPDose/Conc.(drug) : -Result : PositiveRemark : Result: Co-administration of Rg3 and cisplatin more substantially inhibited the expression of Ki-67, VEGF and CD34 and enhanced apoptosis compared with mice treated with Rg3 or cisplatin alone.Note : CT-26 mouse colon cancer cells (2x10^6 cells) suspended in 0.1 ml phosphate buffered saline (PBS) were subcutaneously injected into the right flanks of the mice. Twenty-four hours later, the mice were given Rg3 (5 or 10 mg/kg body weight (BW)) in PBS via oral gavage. Two hours later, cisplatin (2 or 5 mg/kg BW) dissolved in PBS was intraperitoneally injected. Rg3 and/or cisplatin were administered once per day for 15 days.
Part Used : รากActivity : DRUG INTERACTIONSolvent/Active Compound : ginsenoside Rg3Type of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : CT-26 cell-inoculated group treated with 5 mg/kg Rg3 plus 5 mg/kg cisplatin, once daily.Duration : 15 daysType of interaction : PharmacodynamicsInteraction with drug : Cisplatin*/CDDPDose/Conc.(drug) : -Result : PositiveRemark : Result: Treatment with Rg3 remarkably reversed these cisplatin-induced decreases in tissue weights (kidney and liver) and increases in serum biochemical parameters (BUN, AST, ALT) in a dose-dependent manner.Note : CT-26 mouse colon cancer cells (2x10^6 cells) suspended in 0.1 ml phosphate buffered saline (PBS) were subcutaneously injected into the right flanks of the mice. Twenty-four hours later, the mice were given Rg3 (5 or 10 mg/kg body weight (BW)) in PBS via oral gavage. Two hours later, cisplatin (2 or 5 mg/kg BW) dissolved in PBS was intraperitoneally injected. Rg3 and/or cisplatin were administered once per day for 15 days.
Part Used : รากActivity : DRUG INTERACTIONSolvent/Active Compound : ginsenoside Rg3Type of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : CT-26 cell-inoculated group treated with 10 mg/kg Rg3 plus 5 mg/kg cisplatin, once daily.Duration : 15 daysType of interaction : PharmacodynamicsInteraction with drug : Cisplatin*/CDDPDose/Conc.(drug) : -Result : PositiveRemark : Result: Treatment with Rg3 remarkably reversed these cisplatin-induced decreases in tissue weights (kidney and liver) and increases in serum biochemical parameters (BUN, AST, ALT) in a dose-dependent manner.Note : CT-26 mouse colon cancer cells (2x10^6 cells) suspended in 0.1 ml phosphate buffered saline (PBS) were subcutaneously injected into the right flanks of the mice. Twenty-four hours later, the mice were given Rg3 (5 or 10 mg/kg body weight (BW)) in PBS via oral gavage. Two hours later, cisplatin (2 or 5 mg/kg BW) dissolved in PBS was intraperitoneally injected. Rg3 and/or cisplatin were administered once per day for 15 days.
Part Used : รากActivity : DRUG INTERACTIONSolvent/Active Compound : ginsenoside Rg3Type of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : CT-26 cell-inoculated group treated with 5 mg/kg Rg3 plus 5 mg/kg cisplatin, once daily.Duration : 15 daysType of interaction : PharmacodynamicsInteraction with drug : Cisplatin*/CDDPDose/Conc.(drug) : -Result : PositiveRemark : Result: Rg3 treatment prevented these cisplatin-mediated increases in serum NO and tissue MDA levels and decreases in tissue GSH levels.Note : CT-26 mouse colon cancer cells (2x10^6 cells) suspended in 0.1 ml phosphate buffered saline (PBS) were subcutaneously injected into the right flanks of the mice. Twenty-four hours later, the mice were given Rg3 (5 or 10 mg/kg body weight (BW)) in PBS via oral gavage. Two hours later, cisplatin (2 or 5 mg/kg BW) dissolved in PBS was intraperitoneally injected. Rg3 and/or cisplatin were administered once per day for 15 days.
Part Used : รากActivity : DRUG INTERACTIONSolvent/Active Compound : ginsenoside Rg3Type of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : CT-26 cell-inoculated group treated with105 mg/kg Rg3 plus 5 mg/kg cisplatin, once daily.Duration : 15 daysType of interaction : PharmacodynamicsInteraction with drug : Cisplatin*/CDDPDose/Conc.(drug) : -Result : PositiveRemark : Result: Rg3 treatment prevented these cisplatin-mediated increases in serum NO and tissue MDA levels and decreases in tissue GSH levels.Note : CT-26 mouse colon cancer cells (2x10^6 cells) suspended in 0.1 ml phosphate buffered saline (PBS) were subcutaneously injected into the right flanks of the mice. Twenty-four hours later, the mice were given Rg3 (5 or 10 mg/kg body weight (BW)) in PBS via oral gavage. Two hours later, cisplatin (2 or 5 mg/kg BW) dissolved in PBS was intraperitoneally injected. Rg3 and/or cisplatin were administered once per day for 15 days.
